Anti-cancer effects by the green tea catechins
绿茶儿茶素的抗癌作用
基本信息
- 批准号:7050219
- 负责人:
- 金额:$ 21.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-06 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:alternative medicineantineoplasticsapoptosisbiological productscarcinogenesis inhibitorcell linechemopreventioncolorectal neoplasmsflavonoidsgene expression profilinggene induction /repressiongenetic transcriptionhuman genetic material taglaboratory mousenutrition aspect of cancernutrition related tagteatranscription factor
项目摘要
DESCRIPTION (provided by applicant): There is persuasive epidemiological evidence that consumption of dietary polyphenolic plant-derived compounds reduce chronic disease such as cancer. Many laboratory studies including us have shown the inhibitory effect of dietary compounds including resveratrol, genistein, and diaryl disulfide against carcinogenesis in vivo and in vitro. Green tea and its constituent polyphenols (catechins) have been shown to possess anti-tumor properties in a wide variety of experimental systems. Some reports are suggesting an involvement of p53 tumor suppressor proteins, but others do not. Thus, the exact molecular mechanism by which green tea induce anti-tumorigenic effect is not clear. One promising mechanism is the induction of apoptosis by catechins. Indeed, catechins have been known to be associated with the induction of apoptosis. In this regard, our hypothesis of this novel proposal is that the cancer chemopreventive effect of green tea components including catechin (-) epigallocatechin 3-gallate (EGCG), epicatechin gallate (ECG), epigallocatechin (EGC), and epicatechin (EC) is through the induction of apoptotic mechanisms involving the induction of a newly identified TGF-beta superfamily protein, NAG-1 (Nonsteroidal anti-inflammatory drug activated gene). The rationale for this hypothesis is based on the followings: 1) identification of the NAG-1 gene as a dietary induced gene, 2) higher NAG-1 expression in normal colonic epithelial than adjacent tumor cells, 3) NAG-1 has pro-apoptotic and anti-tumorigenic activities reported by us and other groups. Therefore, the overall goal of this project is to identify single catechins or the combinations of catechins for higher NGA-1 inducer in human colorectal cancer cells. To investigate the molecular mechanisms of which a green tea component or combination of them induces NAG-1 expression, we will use two different models, HCT- 116 human colorectal adenocarcinoma cells and mouse model system with following specific aims: 1. Define transcriptional regulatory mechanisms responsible for NAG-1 induction by ECG and other catechins. 2. Profile changes in gene expression following ECG treatment. 3. Compare the preventative and therapeutic efficacy of individual and combination catechins in animal models of colorectal cancer.
描述(由申请人提供):有令人信服的流行病学证据表明,食用多酚植物衍生化合物可减少慢性疾病,如癌症。包括我们在内的许多实验室研究已经表明,白藜芦醇、染料木黄酮和二芳基二硫醚等膳食化合物在体内和体外对致癌作用具有抑制作用。绿色茶及其成分多酚(儿茶素)已被证明在各种各样的实验系统中具有抗肿瘤特性。一些报告表明p53肿瘤抑制蛋白的参与,但其他人没有。因此,绿色茶诱导抗肿瘤作用的确切分子机制尚不清楚。一个有前途的机制是儿茶素诱导细胞凋亡。事实上,已知儿茶素与细胞凋亡的诱导有关。在这方面,我们对这一新提议的假设是,包括儿茶素(-)表没食子儿茶素3-没食子酸酯(EGCG)、表儿茶素没食子酸酯(ECG)、表没食子儿茶素(EGC)和表儿茶素(EC)的绿色茶组分的癌症化学预防作用是通过诱导凋亡机制实现的,所述凋亡机制涉及诱导新鉴定的TGF-β超家族蛋白NAG-1(非甾体抗炎药活化基因)。这一假说的理论基础是:1)NAG-1基因被鉴定为饮食诱导基因,2)NAG-1在正常结肠上皮中的表达高于邻近的肿瘤细胞,3)NAG-1具有促凋亡和抗肿瘤活性。因此,本项目的总体目标是鉴定单一儿茶素或儿茶素组合在人结直肠癌细胞中的更高NGA-1诱导剂。为了研究绿色茶成分或它们的组合诱导NAG-1表达的分子机制,我们将使用两种不同的模型,HCT- 116人结直肠腺癌细胞和小鼠模型系统,具体目的如下:1.定义负责ECG和其他儿茶素诱导NAG-1的转录调节机制。2. ECG治疗后基因表达谱的变化。3.在结直肠癌动物模型中比较单独和组合儿茶素的预防和治疗效果。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Anti-proliferative effect of horehound leaf and wild cherry bark extracts on human colorectal cancer cells.
- DOI:10.3892/or.15.1.275
- 发表时间:2006
- 期刊:
- 影响因子:4.2
- 作者:K. Yamaguchi;J. Liggett;Nam-Cheol Kim;S. Baek
- 通讯作者:K. Yamaguchi;J. Liggett;Nam-Cheol Kim;S. Baek
A potential proliferative gene, NUDT6, is down-regulated by green tea catechins at the posttranscriptional level.
- DOI:10.1016/j.jnutbio.2008.11.002
- 发表时间:2010-02
- 期刊:
- 影响因子:0
- 作者:Sukhthankar M;Choi CK;English A;Kim JS;Baek SJ
- 通讯作者:Baek SJ
Molecular targets of dietary polyphenols with anti-inflammatory properties.
- DOI:10.3349/ymj.2005.46.5.585
- 发表时间:2005-10-31
- 期刊:
- 影响因子:2.4
- 作者:Yoon JH;Baek SJ
- 通讯作者:Baek SJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SEUNG Joon BAEK其他文献
SEUNG Joon BAEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SEUNG Joon BAEK', 18)}}的其他基金
Transcription Regulation and Biological Function of NAG1
NAG1的转录调控及生物学功能
- 批准号:
6799937 - 财政年份:2003
- 资助金额:
$ 21.28万 - 项目类别:
Transcription Regulation and Biological Function of NAG1
NAG1的转录调控及生物学功能
- 批准号:
6610681 - 财政年份:2003
- 资助金额:
$ 21.28万 - 项目类别:
Transcription Regulation and Biological Function of NAG1
NAG1的转录调控及生物学功能
- 批准号:
6910744 - 财政年份:2003
- 资助金额:
$ 21.28万 - 项目类别:
相似海外基金
Novel Substrate Competitive Bcr-Abl Inhibitor Active Against Gleevec-Resistant CM
新型底物竞争性 Bcr-Abl 抑制剂对格列卫耐药 CM 具有活性
- 批准号:
7046281 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
MECHANISMS BY WHICH IFN-GAMMA SEPARATES GVHD AND GVL
IFN-γ 分离 GVHD 和 GVL 的机制
- 批准号:
7158088 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
Targeted Therapy of Lyn in Myelodysplastic Syndrome
Lyn 治疗骨髓增生异常综合征的靶向治疗
- 批准号:
7034786 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
Proapoptotic Therapy for B-cell Non Hodgkin's Lymphoma
B 细胞非霍奇金淋巴瘤的促凋亡治疗
- 批准号:
7056286 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
Analysis of Patient Tumor Responses to Apo2L/TRAIL
患者肿瘤对 Apo2L/TRAIL 的反应分析
- 批准号:
7034793 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
Efficacy and toxicity of TRAIL against gliomas
TRAIL对抗胶质瘤的功效和毒性
- 批准号:
7033212 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
Novel beta-Lactams as New Anti-Cancer Agents
新型 β-内酰胺作为新型抗癌药物
- 批准号:
7163260 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
Dysfunctional Telomeres, Checkpoints and Aging
功能失调的端粒、检查点和衰老
- 批准号:
7065017 - 财政年份:2006
- 资助金额:
$ 21.28万 - 项目类别:
Inhibition of Bcl-2 and Head & Neck Tumor Angiogenesis
Bcl-2 和 Head 的抑制
- 批准号:
6903214 - 财政年份:2005
- 资助金额:
$ 21.28万 - 项目类别:














{{item.name}}会员




